---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011227"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T15:05:48.712623+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Armata posts Q2 2025 operating loss; announces positive AP-SA02 trial results and $15M credit from Innoviva

## Summary
- Q2 2025 operating loss of $6.8M vs. $11.9M loss in Q2 2024; cash at $4.3M as of June 30, 2025.
- Entered $15M secured credit agreement with Innoviva at 14% interest, matures Jan 2029; proceeds to fund AP-SA02 development.
- Positive topline results from Phase 1b/2a diSArm trial: met primary endpoints, improved clinical outcomes, no treatment-related SAEs.
- Received additional $4.65M non-dilutive funding from U.S. Department of Defense through MTEC.
- Plans end-of-Phase 2 meeting with FDA in H2 2025; expects to start Phase 3 pivotal trial in 2026.

## SEC filing metadata
- accession: 0001558370-25-011227
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/0001558370-25-011227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/armp-20250811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011227
- JSON: https://secwatch.observer/filing/0001558370-25-011227.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011227.txt

## Key facts
- Debt Financings
  Armata Pharmaceuticals, Inc. incurred term loan of $15 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.
  - Instrument: term loan
  - Principal: $15 million
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Rate: 14.0% per annum
  - Maturity: January 11, 2029
  - Event: incurrence
  source text: The August 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $15 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/0001558370-25-011227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.